

## OBSERVATIONAL STUDY

OPEN

# Can We Reduce Negative Blood Cultures With Clinical Scores and Blood Markers? Results From an Observational Cohort Study

Svenja Laukemann, MD, Nina Kasper, Prasad Kulkarni, PhD, Deborah Steiner, MD, Anna Christina Rast, MD, Alexander Kutz, MD, Susan Felder, MD, Sebastian Haubitz, MD, Lukas Faessler, Andreas Huber, MD, Christoph A. Fux, MD, Beat Mueller, MD, and Philipp Schuetz, MD, MPH

**Abstract:** Only a small proportion of blood cultures routinely performed in emergency department (ED) patients is positive. Multiple clinical scores and biomarkers have previously been examined for their ability to predict bacteremia. Conclusive clinical validation of these scores and biomarkers is essential.

This observational cohort study included patients with suspected infection who had blood culture sampling at ED admission. We assessed 5 clinical scores and admission concentrations of procalcitonin (PCT), C-reactive protein (CRP), lymphocyte and white blood cell counts, the neutrophil-lymphocyte count ratio (NLCR), and the red blood cell distribution width (RDW). Two independent physicians assessed true blood culture positivity. We used logistic regression models with area under the curve (AUC) analysis.

Of 1083 patients, 104 (9.6%) had positive blood cultures. Of the clinical scores, the Shapiro score performed best (AUC 0.729). The best biomarkers were PCT (AUC 0.803) and NLCR (AUC 0.700). Combining the Shapiro score with PCT levels significantly increased the AUC to 0.827. Limiting blood cultures only to patients with either a Shapiro score of  $\geq 4$  or PCT  $> 0.1 \mu\text{g/L}$  would reduce negative sampling by 20.2% while still identifying 100% of positive cultures. Similarly, a Shapiro score  $\geq 3$  or PCT  $> 0.25 \mu\text{g/L}$  would

reduce cultures by 41.7% and still identify 96.1% of positive blood cultures.

Combination of the Shapiro score with admission levels of PCT can help reduce unnecessary blood cultures with minimal false negative rates.

The study was registered on January 9, 2013 at the 'ClinicalTrials.gov' registration web site (NCT01768494).

(*Medicine* 94(49):e2264)

**Abbreviations:** AUC = area under the curve, CAP = community-acquired pneumonia, CRP = C-reactive protein, ED = emergency department, NLCR = neutrophil-lymphocyte count ratio, OR = odds ratio, PCT = procalcitonin, RDW = red blood cell distribution width, WBC = white blood cell counts.

## INTRODUCTION

Although blood cultures are routinely collected in patients with suspected infection presenting to the emergency department (ED), their sensitivity for bacteremias is low, with  $< 10\%$  of cultures showing growth of bacteria.<sup>1</sup> Moreover, contamination limits their specificity.<sup>2</sup>

Editor: Isobel Ford.

Received: September 30, 2015; revised: November 5, 2015; accepted: November 15, 2015.

From the University Department of Internal Medicine, Medical Faculty of the University of Basel, Kantonsspital Aarau, Switzerland (SL, NK, DS, ACR, AK, SF, LF, BM, PS); Asclepius Medical Communications LLC, Ridgewood, NJ, USA (PK); University Clinic of Infectious Diseases, University Hospital Bern (SH); Institute of Psychology, University of Bern (LF); Department of Laboratory Medicine, Kantonsspital (AH); and Clinic of Infectious Diseases, Kantonsspital Aarau, Switzerland (CAF).

Correspondence: Philipp Schuetz, University Department of Medicine, Kantonsspital Aarau, Telstrasse, Aarau, Switzerland (e-mail: schuetzph@gmail.com).

Supplemental Digital Content is available for this article.

SL and NK contributed equally to this study.

Authors' contributions: SL, NK, PS, CF, and BM conceptualized and designed the study. SL, ACR, AK, DS, SF, CF, AH, CF, LF, and PS contributed to the acquisition, analysis, and interpretation of the data. SL, NK, PK, and PS drafted the manuscript, with all authors contributing to critical revision of the manuscript for important intellectual content. Statistical analysis was performed by SL and PS. BM and PS obtained funding for the study, whereas AH, LF, and SH provided administrative, technical, or material support. The study was supervised by CF, AH, BM, and PS. SL, NK, and PS had full access to all data and take responsibility for the integrity of the data and the accuracy of the data analysis.

All authors have (1) made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; (2) have been involved in drafting the manuscript or revising it critically for important intellectual content; (3) have given the final approval of the version to be published; and (4) agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors have read and approve of the final version of the manuscript.

Competing interests: this work was supported in part by the Swiss National Science Foundation (SNSF Professorship, PP00P3\_150531/1, 32003B\_135222), the Swiss Academy for Medical Sciences (Schweizerische Akademie der Medizinischen Wissenschaften [SAMW]), and the Research Council of the Kantonsspital Aarau, Switzerland (1410.000.044). No commercial sponsor had any involvement in the design or conduct of any aspect of this study, including collection, management, analysis, and interpretation of the data, preparation, review, and approval of the manuscript, and decision to submit the manuscript for publication. AK, BM, and PS have received support from BRAHMS AG (now Thermo Fisher Scientific Biomarkers) to attend meetings and fulfill speaking engagements. BM and PS have received support from bioMérieux to attend meetings and fulfill speaking engagements and have received research grants from both companies, whereas BM has served as a consultant to both companies. All other authors declare no competing interests.

The authors have no conflicts of interest to disclose.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ISSN: 0025-7974

DOI: 10.1097/MD.0000000000002264

Multiple studies have evaluated clinical scores for their utility in the prediction of bacteremia with the aim to improve the (pre-test) probability of positive culture results. A study conducted by Shapiro and colleagues enrolled 3730 ED patients with suspected infections and found 13 clinical parameters integrated into a single clinical score to be able to predict positive cultures with high accuracy.<sup>3</sup> This score, which incorporated major and minor criteria, was also externally validated and proved to be a sensitive but not specific predictor of bacteremia.<sup>4</sup> Another bacteremia prediction model proposed by Lee and colleagues found 7 clinical variables to accurately predict bacteremia in a total of 2422 patients with community-acquired pneumonia (CAP).<sup>5</sup> Jones and colleagues studied 270 patients and found systemic inflammatory response syndrome (SIRS) criteria, the basis of the sepsis definition, to be predictive of bacteremia.<sup>6</sup> Metersky and colleagues studied 13,043 patients with CAP and found the absence of recent antibiotic treatment, liver disease, 3 vital signs, and 3 laboratory abnormalities to be relatively accurate predictors of bacteremia.<sup>7</sup> Finally, Tokuda and colleagues studied 526 patients with acute febrile illness and generated 3 different risk groups for bacteremia with 2 prediction algorithms (Tokuda scores I and II).<sup>8</sup> The 5 clinical scores described above are summarized in full detail in Appendix 1.

In addition to the clinical scores discussed above, biomarkers that correlate with the probability of bacteremia have also been described. Several studies have found procalcitonin (PCT) levels to predict blood culture results in patients with pneumonia,<sup>9–13</sup> urinary tract infections,<sup>14</sup> sepsis,<sup>15</sup> and acute febrile illness.<sup>16</sup> Similar data are available for C-reactive protein (CRP),<sup>13,17</sup> neutrophil-lymphocyte count ratio (NLCR),<sup>18</sup> and lymphocytopenia,<sup>18,19</sup> with significant differences in levels of these biomarkers between bacteremic patients and patients with negative blood cultures. Finally, red blood cell distribution width (RDW) has been proposed as a mortality marker for bacteremia.<sup>20</sup>

Most of these clinical scores have only been evaluated in patients with CAP,<sup>5,7</sup> but not in a more heterogeneous, clinically challenging medical patient population presenting to the ED with suspected infection. We, therefore, aimed to validate the prognostic potential of these clinical scores alone and in combination with novel biomarkers in an ED patient population with suspected infection.

## METHODS

### Study Design and Setting

This is an observational cohort study. We prospectively included all consecutive medical patients with suspected infection presenting to the emergency department of a Swiss tertiary care hospital with additional regional primary and secondary care functions between February 2013 and October 2013 who had initial blood culture samples drawn. Blood cultures were drawn at the discretion of the treating physician. All patients were participants in the TRIAGE project, a prospective, observational study that aimed to devise an algorithm to optimize triage of adult patients with medical emergencies.<sup>21,22</sup>

The aim of this study was to compare 5 different clinical scores and 6 biomarkers for their ability to predict blood culture positivity. The primary endpoint was true blood culture positivity as assessed by 2 independent physicians and an infectious disease specialist according to Centers for Disease Control and Prevention (CDC) criteria (<http://www.cdc.gov/getsmart/healthcare/implementation/clinicianguide.html>).

Given that this was an observational quality control study, the Institutional Review Board (IRB) of the Canton of Aargau approved the study and waived the need for informed consent (approval number EK 2012/059). The study was registered at the “ClinicalTrials.gov” registration web site (NCT01768494).

### Participants and Definitions

Infections were classified on the basis of the main organ involved into the following categories: upper respiratory tract infections, lower respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, central nervous system infections, endocarditis, foreign-material associated infections, and “other” infections. Excluded were patients who directly presented to the surgical ward and pediatric patients < 18 years of age.

In all patients, 2 pairs of blood culture samples for both aerobic and anaerobic cultures (equalling 40 mL of blood altogether) were collected before initiation of antibiotic therapy. Blood cultures were processed using an automated colorimetric detection system (BacT/ALERT, bioMérieux, Durham, NC).<sup>23</sup> If blood culture bottles indicated bacterial growth, samples were Gram stained and subcultured. Identification of the pathogen was performed according to routine laboratory procedures. A blood culture was considered truly positive when it yielded a pathogen typical for the infection site. The evaluation was done by 2 independent physicians. In case of uncertainty, the case was discussed with an infectious disease specialist. The following species were usually considered to be contaminants: coagulase-negative Staphylococci, *Corynebacterium* species, and *Propionibacterium* species, unless an association with intravascular catheters/devices was suspected. In 1 case of a central line-associated infection and 1 case with clinical suspicion of endocarditis, infections with coagulase-negative Staphylococci were considered to be true infections (Appendix 2).

### Clinical Examination and Laboratory Data

In all patients, we recorded pertinent initial vital signs (eg, blood pressure and heart rate) and clinical parameters (eg, chills, vomiting, and comorbidities). Clinical information including socio-demographics, and patient outcomes were assessed prospectively until hospital discharge using the routinely gathered information from the hospital electronic medical system used for coding of Diagnosis-Related Group (DRG) codes.

Samples for later measurement of biomarkers were collected upon ED admission. The following markers were measured as part of routine care: CRP (normal range < 3.0 mg/L), albumin (normal range: 34–50 g/L), WBC (normal range: 4–10 × 10<sup>9</sup>/L), urea (normal range: 2.0–7.0 mmol/L, equals blood urea nitrogen [BUN] in mg/dL divided by 2.8), creatinine (normal range 80–115 μmol/L, divide by 88 for mg/dL), neutrophil percentage/proportion (normal range: 40–85%), neutrophil bands (normal range 0–10%), platelets (normal range 140–400 × 10<sup>9</sup>/L),<sup>12,24</sup> plasma sodium (normal range: 136–146 mmol/L), and red blood cell distribution width (RDW) (normal range: < 15%). The neutrophil-lymphocyte count ratio (NLCR) was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count.

In addition, we measured PCT levels post hoc with an automated rapid sensitive assay (KRYPTOR PCT; Thermo Scientific Biomarkers [formerly BRAHMS AG], Hennigsdorf, Germany; lower limit of detection: 0.02 μg/L).<sup>25</sup>

## Clinical Scores and Biomarkers

The clinical bacteremia scores including the Shapiro score,<sup>3,4</sup> the Lee score,<sup>5,6</sup> the SIRS criteria,<sup>4,6</sup> the Metersky score,<sup>9</sup> and the Tokuda score I and II<sup>8,22</sup> are summarized in full detail in Appendix 1.

In addition, we also focused on several biomarkers that have been found to predict positive cultures. Biomarkers were used as continuous variables and at predefined cut-offs. First, we measured PCT using Kryptor technology and cut-off values were defined as 0.1 µg/L, 0.25 µg/L, 0.5 µg/L, and 1.0 µg/L based on previous studies.<sup>9,12,23,24,26</sup> We used the published cut-offs of  $\geq 10$  and  $\geq 12$  for NLCR<sup>18</sup> and  $< 1 \times 10^9$  g/L for absolute lymphocytopenia.<sup>27</sup> A RDW cut-off of  $>15\%$  was used as previously described.<sup>20</sup>

## Statistical Analysis

This report adheres to the STROBE guidelines for reporting observational studies.<sup>28</sup> Discrete variables are expressed as counts (percentage) and continuous variables as medians and interquartile ranges (IQR). Frequency comparison was done by the chi square test. The 2-group comparison Mann–Whitney *U* test was used. To assess the prognostic performance of different parameters in predicting blood culture positivity, logistic regression analysis was used. We used biomarker levels as continuous variables and at predefined cut-offs as defined above. Logarithmic transformation of biomarker levels was used to obtain normal distribution for skewed variables. Receiver operating characteristics (ROC) were calculated, with the area under the curve being a measure of discrimination. The area under the ROC curve (AUC) is thus a summary measure over criteria and cut-point choices. The AUC summary equals the probability that the underlying classifier will score a randomly drawn positive sample higher than a randomly drawn negative sample. To test whether the biomarker levels improve clinical scores, we compared the nested logistic regression model with clinical scores and biomarkers with a model limited to the clinical scores alone. We also performed subgroup analyses to assess the performance of the different scores and markers within different types of infections and in Gram-positive and Gram-negative infections. We used STATA 12.1 (Stata Corp, College Station, TX). All testing was 2-tailed, with  $P < 0.05$  considered as indicating statistical significance.

## RESULTS

### Baseline Parameters

The median age of all included 1083 patients was 67 years (IQR 53–78) and 57.6% were males. True bacteremia was detected in 104 patients (9.6%). A detailed list of detected pathogens is presented in Appendix 2. A total of 28 patients (2.6% of all patients, 21.2% of those with positive blood cultures [28/132]) had contaminated blood cultures.

Table 1 shows patient characteristics on admission overall and separated according to blood culture results. Patients with positive cultures had less frequent antibiotic pretreatment and a lower diastolic blood pressure, whereas the core body temperature was significantly higher (38.5 °C vs 38.0 °C,  $P < 0.001$ ). Laboratory analysis showed that CRP, NLCR, albumin, and urea were significantly higher in patients with positive blood cultures, whereas the lymphocyte count, RDW, and sodium were significantly lower. In addition, patients with positive blood cultures had almost 8.5-fold higher PCT levels compared to patients with negative cultures (1.69 vs 0.20 µg/L;  $P < 0.001$ ).

As for in-hospital outcomes, patients with positive blood cultures were more frequently transferred to the ICU (12.5% vs 6.1%;  $P = 0.01$ ), had an increased length of stay (8 days vs 6 days;  $P = 0.01$ ), and had a significantly higher 30-day mortality rate (15.4% vs 7.7%;  $P = 0.01$ ).

## Clinical Scores and Biomarkers to Predict Positive Blood Cultures

Table 2 displays the performance of the different clinical scores in predicting culture positivity from logistic regression models and discrimination (AUC). Of the clinical scores, the Shapiro score performed best with an AUC 0.729, followed by the Tokuda score II (AUC 0.665). The other clinical scores performed only moderately: Lee score (AUC 0.623), Metersky score (AUC 0.610), SIRS criteria (AUC 0.546), and Tokuda score I (AUC 0.566). Antibiotic pretreatment was a modest negative predictive factor for positivity of blood cultures, with an AUC of 0.552. The best biomarkers were PCT (AUC 0.803), NLCR (AUC 0.700), and lymphocyte counts (AUC 0.675). On the other hand, CRP, RDW, and WBC did not show significant results (AUC 0.645, 0.610, and 0.544, respectively).

## Combination of Clinical Scores and Biomarkers

Combining the Shapiro score and PCT showed the best results, with the AUC of the combined model being 0.827 (Table 3). The NLCR, CRP, or lymphocyte count could not significantly improve the predictive ability of the Shapiro score when combined individually with the latter. Combining the biomarkers PCT, NLCR, CRP, and lymphocyte count together with the Shapiro score resulted in an AUC of 0.817, which was not better than the combination of the Shapiro score and PCT alone.

## Subgroup Analyses

Subgroup analyses (Table 4) showed the best performance of the Shapiro score to be for skin and soft tissue infections (AUC 0.756), urinary tract infections (AUC 0.694), and infections with Gram-negative bacteria (AUC 0.737). The Metersky score had the best performance for skin and soft tissue infections (AUC 0.737). On the other hand, PCT showed the highest AUC for lower respiratory tract infections and infections with Gram-negative bacteria, with AUC values of 0.876 and 0.837, respectively.

## Diagnostic Measures

Table 5 shows the sensitivity, specificity, and positive and negative likelihood ratios for clinical scores, biomarkers, and promising combinations of the two. At a cut-off of  $\geq 2$  points as previously described by Shapiro and colleagues,<sup>3</sup> the sensitivity of the Shapiro score for prediction of positive blood cultures was 95.2%. At a PCT cut-off of 0.1 µg/L, the sensitivity for prediction of positive blood cultures was 99.0%.

We also calculated diagnostic performance measures in a combined model using Shapiro's score and PCT. Limiting blood cultures to patients with either Shapiro scores  $\geq 4$  points or PCT levels  $> 0.1$  µg/L would reduce negative sampling by 20.2% while still identifying 100% of positive cultures. Using Shapiro scores of  $\geq 3$  points or PCT levels  $> 0.25$  µg/L would reduce negative sampling by 41.7% while still identifying 96.1% of positive cultures. (Appendix 3 provides additional details on the 4 patients [3.9%] missed with this algorithm). Finally, using a Shapiro score of  $\geq 5$  points or PCT  $> 1$  µg/L

**TABLE 1.** Baseline Characteristics of Patients Overall and Separated by Blood Culture Positivity and Negative or Contaminated Blood Cultures

	All (N = 1083)	Positive Blood Cultures (n = 104)	Negative/Contaminated Blood Cultures (n = 979)	P Value
General characteristics				
Age	67 (53, 78)	73 (65, 82)	67 (52, 77)	<0.001
Male sex	623 (57.6%)	54 (52.9%)	569 (58.1%)	0.31
Pretreatment				
Antibiotic pretreatment	165 (15.2%)	6 (5.8%)	159 (16.2%)	0.01
Comorbidities				
Hypertension	333 (30.7%)	39 (37.5%)	294 (30.0%)	0.12
Chronic heart failure	60 (5.5%)	9 (8.7%)	51 (5.2%)	0.14
Coronary heart disease	58 (5.4%)	10 (9.6%)	48 (4.9%)	0.04
Chronic lung disease	76 (7.0%)	5 (4.8%)	71 (7.3%)	0.35
Dementia	42 (3.9%)	4 (3.8%)	38 (3.9%)	0.99
Stroke	31 (2.9%)	2 (1.9%)	29 (3.0%)	0.55
Renal insufficiency	192 (17.7%)	30 (28.8%)	162 (16.5%)	<0.05
Chronic liver disease	136 (12.6%)	19 (18.3%)	117 (12.0%)	0.06
Diabetes mellitus (any type)	121 (11.2%)	12 (11.5%)	109 (11.1%)	0.90
Neoplastic disease	198 (18.3%)	24 (23.1%)	174 (17.8%)	0.18
Main infection site				<0.001
Suspected or confirmed bacterial infections				
Lower respiratory tract	375 (34.6%)	15 (14.4%)	360 (36.8%)	
Urinary tract	180 (16.6%)	42 (40.4%)	138 (14.1%)	
Intra-abdominal	135 (12.5%)	23 (22.1%)	112 (11.4%)	
Skin and soft tissue	59 (5.4%)	5 (4.8%)	54 (5.5%)	
Central nervous system (meningitis)	19 (1.8%)	1 (1.0%)	18 (1.8%)	
Heart (endocarditis)	9 (0.8%)	8 (7.7%)	1 (0.1%)	
Upper respiratory tract	20 (1.8%)	4 (3.8%)	16 (1.6%)	
Foreign material	12 (1.1%)	3 (2.9%)	9 (0.9%)	
Infection site unknown (fever of unknown origin)	91 (8.4%)	1 (1.0%)	90 (9.2%)	
Other infections or no final diagnosis of infection				
Other infections	41 (3.8%)	2 (1.9%)	39 (4.0%)	
No final diagnosis of infection	142 (13.1%)	0 (0.0%)	142 (14.5%)	
Clinical variables				
Pulse rate, bpm	94 (80, 107)	94 (82, 108)	94 (80, 107)	0.36
Systolic blood pressure, mm Hg	132 (117, 148)	132 (114, 146)	132 (117, 149)	0.54
Diastolic blood pressure, mm Hg	76 (66, 86)	72 (60, 80)	76 (67, 87)	<0.001
Temperature, °C	38.0 (37.3, 38.7)	38.5 (37.5, 39.1)	38.0 (37.3, 38.7)	<0.001
Chills	196 (18.1%)	28 (26.9%)	168 (17.2%)	0.01
Vomiting	153 (14.1%)	19 (18.3%)	134 (13.7%)	0.20
Laboratory values				
CRP, mg/L	83 (28, 155)	143 (54, 208)	78 (25, 150)	<0.001
PCT, µg/L	0.22 (0.11, 0.77)	1.69 (0.44, 12.30)	0.20 (0.11, 0.55)	<0.001
WBC, × 10 <sup>9</sup> /L	10.3 (7.1, 14.2)	11.6 (7.6, 15.4)	10.2 (7.0, 14.0)	0.14
NLCR	8 (4, 15)	17 (9, 28)	8 (4, 14)	<0.001
Lymphocyte count, × 10 <sup>9</sup> /L	0.9 (0.54, 1.47)	0.6 (0.36, 0.9)	0.94 (0.57, 1.54)	<0.001
RDW, %	216 (168, 289)	201 (148, 254)	219 (171, 291)	0.01
Platelets, × 10 <sup>9</sup> /L	137 (134, 139)	136 (133, 139)	137 (134, 139)	0.18
Sodium, mmol/L	33.5 (29.3, 37.1)	30.3 (26.2, 34.5)	33.8 (29.6, 37.2)	<0.001
Albumin, g/L	6.3 (4.6, 9.6)	7.5 (5.4, 13.8)	6.2 (4.5, 9.2)	<0.001
Urea, mmol/L	13.9 (13.0, 15.5)	14.6 (13.5, 16.3)	13.9 (12.9, 15.4)	<0.001
Outcomes				
Length of stay, days	6 (4, 10)	8 (4, 16)	6 (4, 10)	0.01
ICU-admission	73 (6.7%)	13 (12.5%)	60 (6.1%)	0.01
30-day mortality	91 (8.4%)	16 (15.4%)	75 (7.7%)	0.01

Data are presented as no. (%) or median (interquartile range). CRP = C-reactive protein, NLCR = neutrophil-lymphocyte count ratio, PCT = procalcitonin, RDW = red blood cell distribution width (%), WBC = white blood cell count.

**TABLE 2.** Results of Univariate Regression Analysis and AUC

Characteristic	Score Points/Cut-offs	All (N = 1083)	Positive Blood Cultures (N = 104)	Negative/Contaminated Blood Cultures (N = 979)	OR (95% CI)*	AUC
Clinical scores						
Shapiro score, mean (SD)		2.5 (1.6)	3.7 (1.6)	2.4 (1.5)	<b>1.52 (1.36–1.71)</b>	0.729
Shapiro score	0	117 (10.8%)	0 (0.0%)	117 (12.0%)	reference	
	1	178 (16.4%)	5 (4.8%)	173 (17.7%)		
	2	288 (26.6%)	20 (19.2%)	268 (27.4%)	<b>4.33 (1.60–11.69)</b>	
	3	232 (21.4%)	26 (25.0%)	206 (21.0%)	<b>7.32 (2.77–19.38)</b>	
	4	144 (13.3%)	19 (18.3%)	125 (12.8%)	<b>8.82 (3.22–24.14)</b>	
	5	78 (7.2%)	20 (19.2%)	58 (5.9%)	<b>20.00 (7.21–55.45)</b>	
	6	29 (2.7%)	8 (7.7%)	21 (2.1%)	<b>22.10 (6.64–73.50)</b>	
	7–15	17 (1.6%)	6 (5.8%)	11 (1.1%)	<b>31.64 (8.36–119.71)</b>	
Lee score, mean (SD)		0.2 (0.4)	0.5 (0.6)	0.2 (0.4)	<b>1.99 (1.32–2.98)</b>	0.623
Lee score, low-risk group	≤ 5	880 (81.3%)	71 (68.3%)	809 (82.6%)	reference	
intermediate-risk group	6–10	194 (17.6%)	32 (30.8%)	162 (16.5%)	<b>2.25 (1.43–3.53)</b>	
high-risk group	≥ 11	9 (0.8%)	1 (1.0%)	8 (0.8%)	1.42 (0.18–11.50)	
SIRS criteria, mean (SD)		1.5 (1.0)	1.6 (0.9)	1.5 (1.1)	1.16 (0.96–1.40)	0.546
SIRS criteria	0	213 (19.7%)	10 (9.6%)	203 (20.7%)	reference	
	1	339 (31.3%)	39 (37.5%)	300 (30.6%)	<b>2.64 (1.29–5.41)</b>	
	2	335 (30.9%)	34 (32.7%)	301 (30.7%)	<b>2.29 (1.11–4.74)</b>	
	3	171 (15.8%)	20 (19.2%)	151 (15.4%)	<b>2.69 (1.22–5.91)</b>	
	4	25 (2.3%)	1 (1.0%)	24 (2.5%)	0.85 (0.10–6.90)	
Metersky score, mean (SD)		1.4 (0.6)	1.6 (0.6)	1.4 (0.6)	<b>2.10 (1.45–3.04)</b>	0.610
Metersky score, low-risk group		83 (7.7%)	4 (3.8%)	79 (8.1%)	reference	
moderate-risk group		511 (47.2%)	33 (31.7%)	478 (48.8%)	1.36 (0.47–3.95)	
high-risk group		489 (45.2%)	67 (64.4%)	422 (43.1%)	<b>3.14 (1.11–8.85)</b>	
Tokuda score I, mean (SD)		0.4 (0.7)	0.6 (0.9)	0.3 (0.7)	<b>1.52 (1.19–1.94)</b>	0.566
Tokuda score I, low-risk group		845 (78.0%)	70 (67.3%)	775 (79.2%)	reference	
intermediate-risk group		89 (8.2%)	7 (6.7%)	82 (8.4%)	0.95 (0.42–2.12)	
high risk group		149 (13.8%)	27 (26.0%)	122 (12.5%)	<b>2.45 (1.51–3.97)</b>	
Tokuda score II, mean (SD)		0.6 (0.7)	1.0 (0.7)	0.6 (0.7)	<b>2.34 (1.59–3.43)</b>	0.665
Tokuda score II, low-risk group		562 (51.9%)	25 (24.0%)	537 (54.9%)	reference	
intermediate-risk group		372 (34.3%)	52 (50.0%)	320 (32.7%)	<b>2.53 (1.08–5.93)</b>	
High-risk group		149 (13.8%)	28 (26.0%)	122 (12.5%)	<b>5.75 (2.30–14.33)</b>	
Other clinical parameters						
Antibiotic pretreatment		165 (15.2%)	6 (5.8%)	159 (16.2%)	<b>0.37 (0.17–0.80)</b>	0.552
Chills		196 (18.1%)	28 (29.6%)	168 (17.2%)	<b>1.83 (1.16–2.89)</b>	0.551
Biomarkers						
CRP, mean (SD)		106 (96)	154 (118)	101 (92)	<b>1.00 (1.00–1.00)</b>	0.645
CRP, cut-offs	≤ 50	422 (39.0%)	24 (23.5%)	398 (40.7%)	reference	
	> 50–100	217 (20.1%)	14 (13.7%)	203 (20.7%)	<b>1.00 (1.00–1.01)</b>	
	> 100–150	162 (15.0%)	18 (17.6%)	144 (14.7%)	1.14 (0.58–2.26)	
	> 150–200	129 (11.9%)	19 (18.6%)	110 (11.2%)	<b>2.86 (1.51–5.42)</b>	
	> 200	151 (14.0%)	27 (26.5%)	124 (12.7%)	<b>3.46 (2.01–6.49)</b>	
PCT, mean (SD)		2.91 (11.42)	12.1 (26.35)	1.93 (7.83)	<b>1.04 (1.03–1.06)</b>	0.803
PCT cut-offs	≤ 0.1	240 (22.2%)	1 (1%)	239 (24.4%)	reference	
	> 0.1–0.25	354 (32.7%)	16 (15.4%)	338 (34.5%)	<b>11.31 (1.49–85.89)</b>	
	> 0.25–0.5	154 (14.2%)	13 (12.5%)	141 (14.4%)	<b>22.04 (2.85–170.24)</b>	
	> 0.5–1.0	107 (9.9%)	12 (11.5%)	95 (9.7%)	<b>30.19 (3.87–235.40)</b>	
	> 1.0	228 (21.1%)	62 (59.6%)	166 (17.0%)	<b>89.27 (12.26–650.16)</b>	
WBC, mean (SD)		12.1 (16.0)	11.6 (7.6, 15.4)	10.2 (7.0, 14.0)	1.00 (0.99–1.01)	0.544
WBC, cut-offs	≤ 10	512 (47.7%)	42 (41.6%)	470 (48.3%)	reference	
	> 10–15	333 (31.0%)	30 (29.7%)	303 (31.1%)	1.11 (0.68–1.80)	
	> 15	229 (21.3%)	29 (28.7%)	200 (20.6%)	1.62 (0.98–2.68)	
NLCR, mean (SD)		13 (21)	20 (17)	12 (21)	<b>1.01 (1.00–1.02)</b>	0.700
NLCR cut-offs	< 10	624 (58.3%)	28 (27.7%)	596 (61.4%)	reference	
	≥ 10–12	80 (7.5%)	10 (9.9%)	70 (7.2%)	<b>3.04 (1.42–6.52)</b>	
	≥ 12	367 (34.3%)	63 (62.4%)	304 (31.3%)	<b>4.41 (2.77–7.03)</b>	

Characteristic	Score Points/Cut-offs	All (N = 1083)	Positive Blood Cultures (N = 104)	Negative/Contaminated Blood Cultures (N = 979)	OR (95% CI)*	AUC
Lymphocyte count, mean (SD)		1.8 (3.2)	2.8 (4.0)	1.7 (3.0)	<b>1.07 (1.02–1.11)</b>	0.675
Lymphocyte count, cut-offs	> 1 × 10 <sup>9</sup>	473 (44.1%)	21 (20.8%)	452 (46.5%)	reference	
	< 1 × 10 <sup>9</sup>	600 (55.9%)	80 (79.2%)	520 (53.5%)	<b>3.31 (2.01–5.44)</b>	
RDW, mean (SD)	14.5 (2.3)	15.1 (2.4)	14.4 (2.3)	1.11 (1.03–1.20)	0.610	
RDW, cut-offs	< 15	751 (69.9%)	61 (60.4%)	690 (70.9%)	reference	
	> 15	323 (30.1%)	40 (39.6%)	283 (29.1%)	<b>1.60 (1.04–2.43)</b>	

AUC = area under the curve, CI = confidence interval, CRP = C-reactive protein (mg/L), NLCR = neutrophil-lymphocyte count ratio; lymphocyte count ( $\times 10^9/L$ ), OR = odds ratio, PCT = procalcitonin ( $\mu g/L$ ), RDW = red blood cell distribution width (%), SD = standard deviation, WBC = white blood cell count ( $\times 10^9/L$ ).

\*Confidence intervals that do not overlap the null value of OR = 1 are shown in bold.

would permit reduction of blood cultures by 77.8% and enable the identification of 73.1% of positive cultures.

## DISCUSSION

In this study that included consecutive medical patients presenting to the ED with suspected infection, we validated 5 clinical scores and biomarkers as potential predictors of bacteremia. The Shapiro score was the only score with good performance characteristics (AUC 0.729) which is in line with findings of a previous validation study.<sup>4</sup> This score, when used in our patient population, would have helped reduce the number of blood cultures by 29.6% with minimal loss of sensitivity for true positive blood cultures, which is consistent with potential reduction of blood cultures by 27% in the original publication.<sup>23</sup> Given that there were 1083 blood cultures drawn, a 29.6% reduction would result in ~320 fewer cultures, with a potential cost saving of 46,400 US dollars [USD] (at an estimated cost of 145 USD for 2 sets of blood cultures per patient based on institutional data available at the University Hospital Basel). Additionally, this would reduce the number of false-positive cultures with subsequent investigations.

As for the biomarkers evaluated in this study, PCT proved to be the most reliable predictor of blood culture positivity, which is in line with previous research.<sup>11</sup> Depending on the cut-off applied, PCT levels of < 0.1  $\mu g/L$  identified patients with a low enough risk for bacteremia that unnecessary blood culture sampling could be avoided in these patients, resulting in significant financial benefits. With a PCT cut-off of > 0.1  $\mu g/L$ , only 1 patient (1.0%) with positive blood cultures was missed whereas 24.4% of false negative blood cultures could have been avoided. Limiting blood cultures only to patients with increased PCT levels (ie, > 0.1  $\mu g/L$  or > 0.25  $\mu g/L$ ) would likely result in significant cost benefits even when considering assay costs of ~25 USD per PCT measurement.

Our study evaluating PCT in a broad and unselected ED patient population is novel since most other studies evaluated the accuracy of PCT to predict bacteremia in particular patient populations with specified focal infections such as pneumonia, urinary tract infections, or in patients with disseminated infections such as sepsis.<sup>9–16</sup> To our knowledge, only 1 previous study has evaluated PCT in such a broad ED population with suspected infection.<sup>29</sup> This study, which included an unselected patient population with suspected bloodstream infections, revealed that PCT levels were significantly elevated in patients with positive blood cultures and that PCT levels were

significantly correlated with survival in patients with bacteremia. In our analysis, PCT was found to improve the predictive capabilities of the Shapiro score. To our knowledge, this is the first study to investigate the prognostic capacity of PCT in combination with the Shapiro score.

Our results are also in line with a previous ED-based study in Japan looking at the predictive value of different inflammation markers (PCT, CRP, WBC, platelets) to predict culture positivity.<sup>30</sup> In this study using primary component analysis, PCT and platelets were found to be more helpful compared to CRP and WBC. Also, another recent study comparing the prognostic accuracy of PCT, CRP, and WBC in 513 patients presenting to the ED with signs/symptoms of local infections or sepsis found PCT to be the most accurate biomarker for diagnosis of sepsis and for mortality prediction.<sup>31</sup>

There exist no clear guidelines as to when blood cultures should be drawn.<sup>1</sup> Because of the low yield of true positive results, routine sampling of blood cultures has been questioned.<sup>1,3</sup> On the other hand, increasing antibiotic resistance calls for rapid bacterial identification and resistance testing to optimize treatment.<sup>32</sup> There is thus an unmet need for accurate predictors of bacteremia. A higher pretest probability for true positive results would enable us to define a specific group of patients who would clearly benefit from blood cultures being drawn. Multiple clinical scores and biomarkers have been proposed to address this need. In this context, PCT and the NLCR have been shown to be the most promising ones.<sup>18,33</sup>

Although the vast majority of patients with positive blood cultures had PCT levels > 0.25  $\mu g/L$ , 1 patient with a PCT level < 0.1  $\mu g/L$  and 16 other patients with a PCT level < 0.25  $\mu g/L$  also had positive, noncontaminated blood cultures. Appendix 3 provides additional details on the 17 patients with positive blood cultures but low PCT levels. Out of these, 5 patients [29.4%] suffered from endocarditis. Remarkably, 5 of 9 [55.6%] endocarditis cases with true positive blood cultures had relatively low PCT levels (0.15  $\mu g/L$  to 0.24  $\mu g/L$ ). This finding that PCT is not routinely required to rule in or rule out infective endocarditis is in line with results of other studies.<sup>34–36</sup> Another 8 of the 17 patients (47.1%) presented to the ED within < 24 h of symptom onset, and it is likely that PCT levels may not have reached their peak at this point in time. This hypothesis, however, needs to be evaluated in another prospective study.

In routine clinical practice, blood cultures are often drawn in response to fever.<sup>1</sup> In our study population, however, 30 of the 104 patients with true positive blood cultures (28.8%) had temperatures < 38.0°C and 49 patients (47.1%) had

**TABLE 3.** Combined Models

Model I		AUC	<i>P</i> vs CRP	<i>P</i> vs Shapiro score
Parameter				
Shapiro score		0.729		
CRP		0.645		
Combined		0.757	< 0.01	0.13
Model II				
Parameter		AUC	<i>P</i> vs PCT	<i>P</i> vs Shapiro score
Shapiro score		0.729		
PCT		0.803		
Combined		0.827	0.03	< 0.01
Model III				
Parameter		AUC	<i>P</i> vs NLCR	<i>P</i> vs Shapiro score
Shapiro score		0.729		
NLCR		0.700		
Combined		0.752	0.01	0.27
Model IV				
Parameter		AUC	<i>P</i> vs Lymphocyte count	<i>P</i> vs Shapiro score
Shapiro score		0.729		
Lymphocyte count		0.675		
Combined		0.755	< 0.01	0.04
Model V				
Parameter		AUC		<i>P</i> vs Shapiro score
Shapiro score		0.729		
Combined with CRP, PCT, NLCR and Lymphocyte count		0.817		< 0.01

AUC = area under the curve, CRP = C-reactive protein, NLCR = neutrophil-lymphocyte count ratio, PCT = procalcitonin.

temperatures < 38.5°C. This finding illustrates the limitations with regard to sensitivity and specificity of a single clinical parameter when used in isolation for decision making.

Our study has some limitations. First, the study was conducted at a single center, and the findings may not be readily applicable to other patient groups with different demographic characteristics. Second, due to the lack of clear guidelines concerning indications for obtaining blood cultures, some

patients with fever and infections may not have had blood culture sampling on admission to the ED and are therefore not included in our study population. The decision to obtain the culture was left to the ED physicians' clinical judgment or could even be made by the nursing staff with or without consultation with the clinician. Third, a potential limitation for widespread implementation of the Shapiro score combined with PCT levels > 0.1 µg/L is the large number of predictive factors included in

**TABLE 4.** Subgroup Analyses (AUC)

Infection Type → Characteristic ↓	All (N = 1083)	Lower Respiratory Tract (n = 375)	Urinary Tract (n = 180)	Intra- Abdominal (n = 135)	Skin and Soft Tissue (n = 59)	Immunosuppression (n = 172)	Only Gram-Positive Bacteria (n = 40)	Only Gram- Negative Bacteria (n = 64)
Clinical score								
Shapiro score	0.729	0.665	0.694	0.582	0.756	0.635	0.687	0.756
Lee score	0.623	0.642	0.545	0.653	0.761	0.595	0.656	0.603
SIRS criteria	0.546	0.602	0.546	0.544	0.689	0.492	0.525	0.559
Metersky score	0.610	0.646	0.581	0.534	0.737	0.614	0.647	0.587
Tokuda score I	0.566	0.590	0.518	0.521	0.493	0.439	0.508	0.603
Tokuda score II	0.665	0.686	0.640	0.553	0.604	0.626	0.598	0.708
Biomarkers								
CRP	0.645	0.697	0.632	0.605	0.657	0.686	0.668	0.629
PCT	0.803	0.876	0.760	0.785	0.778	0.790	0.749	0.837
WBC	0.544	0.469	0.479	0.560	0.811	0.460	0.567	0.529
NLCR	0.700	0.579	0.667	0.676	0.932	0.503	0.697	0.701
Lymphocyte count	0.675	0.750	0.653	0.605	0.849	0.563	0.647	0.694
RDW	0.610	0.533	0.566	0.663	0.615	0.535	0.676	0.560

AUC = area under the curve, CRP = C-reactive protein, NLCR = neutrophil-lymphocyte count ratio, PCT = procalcitonin, RDW = red blood cell distribution width, SIRS = systemic inflammatory response syndrome, WBC = white blood cell count.

**TABLE 5. Diagnostic Performance for Prediction of Bacteremia by the Shapiro Score and Biomarkers**

	Sensitivity (95% CI)	Specificity (95% CI)	LR + (95% CI)	LR – (95% CI)	PPV (95% CI)	NPV (95% CI)	Positive BC / Screened BC n (%)	Missed Positive BC n (%)	Avoided Negative BC n (%)
<b>Clinical score/biomarker</b>									
Shapiro score ≥2 points	95.2%	26.6%	1.35	0.16	12.6%	98.3%	99/786	5	290
	89.1%, 98.4%	26.8%, 32.6%	1.27, 1.44	0.07, 0.38	10.3%, 15.1%	96.1%, 99.4%	12.6%	4.8%	29.6%
Shapiro score ≥3 points	76.0%	57.0%	1.77	0.42	15.8	95.7	79/496	2.5	562
	66.6%, 83.8%	53.8%, 60.1%	1.55, 2.01	0.30, 0.60	12.7, 19.3	93.7%, 97.2%	15.9%	24.0%	57.4%
Shapiro score ≥4 points	51.0%	78.0%	2.32	0.63	19.8%	93.7%	52/263	52	768
	41.0%, 60.9%	75.3%, 80.6%	1.86, 2.90	0.52, 0.77	15.2%, 25.1%	91.9%, 95.3%	19.8%	50.0%	78.5%
Shapiro score ≥7points	5.8%	98.9%	5.13	0.95	35.3%	90.8%	6/17	98	968
	2.1%, 12.1%	98.0%, 99.4%	1.94, 13.6	0.91, 1.00	14.2%, 61.7%	88.9%, 92.5%	5.8%	94.2%	98.9%
PCT > 0.1 µg/L	99.0%	24.4%	1.31	0.04	12.2%	99.6%	103/843	1	239
	94.8%, 100%	21.8%, 27.2%	1.26, 1.36	0.01, 0.28	10.1%, 14.6%	97.7%, 100%	12.2%	1.0%	24.4%
PCT > 0.25 µg/L	83.7%	58.9%	2.04	0.28	17.8%	97.1%	87/489	17	577
	75.1%, 90.2%	55.8%, 62.0%	(1.82, 2.28)	0.18, 0.43	14.5%, 21.5%	95.5%, 98.3%	17.8%	16.4%	58.9%
PCT > 0.5 µg/L	71.2%	73.3%	2.67	0.39	22.1%	96.0%	74/335	30	718
	61.4%, 79.6%	70.5%, 76.1%	2.27, 3.13	0.29, 0.53	17.8%, 26.9%	94.3%, 97.3%	22.1%	28.9%	73.3%
PCT > 1 µg/L	59.6%	83.0%	3.52	0.49	27.2%	95.1%	62/228	42	813
	49.5%, 69.1%	80.5%, 85.3%	2.85, 4.34	0.38, 0.62	21.5%, 33.5%	93.4%, 96.4%	27.2%	40.4%	83.0%
NLCR ≥ 10	72.3%	61.4%	1.87	0.45	16.3%	95.5%	73/447	28	596
	62.5%, 80.7%	58.3%, 64.4%	1.62, 2.17	0.33, 0.62	13.0%, 20.1%	93.6%, 97.0%	16.3%	27.7%	61.4%
NLCR ≥ 12	62.4%	68.7%	1.99	0.55	17.2%	94.6%	63/367	38	666
	52.2%, 71.8%	65.6%, 71.6%	1.67, 2.38	0.42, 0.71	13.5%, 21.4%	92.7%, 96.2%	17.2%	37.6%	68.7%
<b>Combined models</b>									
Shapiro score ≥2 points or PCT > 0.25 µg/L	98.1%	24.5%	1.30	0.08	12.1%	99.2%	102/841	2	240
	93.2%, 99.8%	21.8%, 27.3%	1.24, 1.36	0.02, 0.31	10.0%, 14.5%	97.0%, 99.9%	12.1%	1.9%	24.5%
Shapiro score ≥2 points or PCT > 0.5 µg/L	97.1%	27.5%	1.34	0.10	12.5%	98.9%	101/811	3	269
	91.8%, 99.4%	24.7%, 30.4%	1.27, 1.41	0.03, 0.32	10.3%, 14.9%	96.8%, 99.8%	12.5%	2.9%	27.5%
Shapiro score ≥2 points or PCT > 1 µg/L	97.1%	28.6%	1.36	0.10	12.6%	98.9%	101/800	3	280
	91.8%, 99.4%	25.8%, 31.5%	1.29, 1.43	0.03, 0.31	10.4%, 15.1%	96.9%, 99.8%	12.6%	2.9%	28.6%
Shapiro score ≥3 points or PCT > 0.25 µg/L	96.1%	41.7%	1.65	0.09	14.9%	99.0%	100/671	4	408
	90.4%, 98.9%	38.6%, 44.8%	1.54, 1.76	0.04, 0.24	12.3%, 17.8%	97.5%, 99.7%	14.9%	3.9%	41.7%
Shapiro score ≥4 points or PCT > 0.1 µg/L	100%	20.2%	1.25	0.00	11.8%	100%	104/834	0	198
	96.5%, 100%	17.8%, 22.9%	1.21, 1.29	0.00	9.7%, 14.1%	98.2%, 100%	12.5%	0%	20.2%
Shapiro score ≥5 points or PCT > 1 µg/L	73.1%	77.8%	3.30	0.35	25.9%	96.5%	76/293	28	762
	63.5%, 81.3%	75.1%, 80.4%	2.79, 3.89	0.25, 0.48	21.0%, 31.4%	94.9%, 97.6%	25.9%	26.9%	77.8%

BC = blood culture, CI = confidence interval, LR (+) = positive likelihood ratio, LR (–) = negative likelihood ratio, NLCR = neutrophil-lymphocyte count ratio, NPV = negative predictive value, PCT = procalcitonin, PPV = positive predictive value.



the Shapiro score, which makes it complex and difficult to remember. However, the predictors themselves are routinely measured and available soon after gathering the medical history and physical examination in the ED setting. Determining PCT levels takes longer, however, with the need for point-of-care tests. Despite these limitations, the results of our study can be applied to a broad spectrum of internal medicine patients as the study was conducted in a relatively large number of patients.

Our study warrants future work in this area. A multicenter study to include a greater number of patients may help corroborate the findings of this study and reveal interesting new insights. Replication of this study in other facilities with patient populations having different demographic characteristics may also be informative. A study focusing on the application of our methodology to infections of specific body sites may be worthwhile, given that urinary tract infections and intra-abdominal infections were seen to have a higher risk for bacteremia (Table 1).

### CONCLUSIONS

In conclusion, although the Shapiro score is a useful clinical score on its own, combination of the Shapiro score with admission levels of PCT allows clinicians to abstain from ordering a significant number of potentially useless blood cultures, resulting in significant reductions in costs and false-positive results.

Based on the results of this study, a rational approach to blood culture collection may be as follows: for high-risk patients (eg, suspicion of endocarditis, immunosuppressed patients) blood cultures should be collected when  $\geq 4$  Shapiro criteria are fulfilled or when PCT levels are  $> 0.1 \mu\text{g/L}$  because the risk of false negative is minimal (0% in our study); for all other patients blood cultures should be collected when  $\geq 3$  Shapiro criteria are fulfilled or when PCT levels are  $> 0.25 \mu\text{g/L}$  as this cut-off reduces blood cultures by  $>40\%$  with still a low risk of missing a positive culture (3.9%). In accordance with Shapiro and colleagues, we emphasize that careful clinical judgment must be used when applying a general clinical score to an individual patient and that the score should be overridden in instances in which specific circumstances and complex clinical conditions are present.<sup>3</sup>

### ACKNOWLEDGMENTS

We are grateful to all the local physicians, nursing staff, and patients who participated in this study. Especially, we thank the staff of the emergency room, medical clinics, and central laboratories of the Kantonsspital Aarau for their very helpful assistance, patience, and technical support throughout the conduct of the study.

### REFERENCES

- Coburn B, Morris AM, Tomlinson G, et al. Does this adult patient with suspected bacteremia require blood cultures? *JAMA*. 2012;308:502–511.
- Schuetz P, Mueller B, Trampuz A. Serum procalcitonin for discrimination of blood contamination from bloodstream infection due to coagulase-negative staphylococci. *Infection*. 2007;35:352–355.
- Shapiro NI, Wolfe RE, Wright SB, et al. Who needs a blood culture? A prospectively derived and validated prediction rule. *J Emerg Med*. 2008;35:255–264.
- Jessen MK, Mackenhauer J, Hvass AM, et al. Prediction of bacteremia in the emergency department: an external validation of a clinical decision rule. *Eur J Emerg Med*. 2014[Epub ahead of print].
- Lee J, Hwang SS, Kim K, et al. Bacteremia prediction model using a common clinical test in patients with community-acquired pneumonia. *Am J Emerg Med*. 2014;32:700–704.
- Jones GR, Lowes JA. The systemic inflammatory response syndrome as a predictor of bacteraemia and outcome from sepsis. *QJM*. 1996;89:515–522.
- Metersky ML, Ma A, Bratzler DW, et al. Predicting bacteremia in patients with community-acquired pneumonia. *Am J Respir Crit Care Med*. 2004;169:342–347.
- Tokuda Y, Miyasato H, Stein GH. A simple prediction algorithm for bacteraemia in patients with acute febrile illness. *QJM*. 2005;98:813–820.
- Muller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. *Chest*. 2010;138:121–129.
- Schuetz P, Amin DN, Greenwald JL. Role of procalcitonin in managing adult patients with respiratory tract infections. *Chest*. 2012;141:1063–1073.
- Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. *JAMA*. 2009;302:1059–1066.
- Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections—hope for hype? *Swiss Med Weekly*. 2009;139:318–326.
- Zhydkov A, Christ-Crain M, Thomann R, et al. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia. *Clin Chem Lab Med*. 2015;53:559–566.
- van Nieuwkoop C, Bonten TN, van't Wout JW, et al. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. *Crit Care*. 2010;14:R206.
- Riedel S, Melendez JH, An AT, et al. Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department. *Am J Clin Pathol*. 2011;135:182–189.
- Kim MH, Lim G, Kang SY, et al. Utility of procalcitonin as an early diagnostic marker of bacteremia in patients with acute fever. *Yonsei Med J*. 2011;52:276–281.
- Schuetz P, Suter-Widmer I, Chaudri A, et al. Prognostic value of procalcitonin in community-acquired pneumonia. *Eur Respir J*. 2011;37:384–392.
- Loonen AJ, de Jager CP, Tisserams J, et al. Biomarkers and molecular analysis to improve bloodstream infection diagnostics in an emergency care unit. *PLoS One*. 2014;9:e87315.
- Wyllie DH, Bowler IC, Peto TE. Relation between lymphopenia and bacteraemia in UK adults with medical emergencies. *J Clin Pathol*. 2004;57:950–955.
- Yeh CF, Chen KF, Ye JJ, et al. Derivation of a clinical prediction rule for bloodstream infection mortality of patients visiting the emergency department based on predisposition, infection, response, and organ dysfunction concept. *J Microbiol Immunol Infect*. 2014;47:469–477.
- Schuetz P, Hausfater P, Amin D, et al. Biomarkers from distinct biological pathways improve early risk stratification in medical emergency patients: the multinational, prospective, observational TRIAGE study. *Crit Care (London, England)*. 2015;19:377.
- Schuetz P, Hausfater P, Amin D, et al. Optimizing triage and hospitalization in adult general medical emergency patients: the triage project. *BMC Emerg Med*. 2013;13:12.
- Thorpe TC, Wilson ML, Turner JE, et al. BacT/Alert: an automated colorimetric microbial detection system. *J Clin Microbiol*. 1990;28:1608–1612.
- Schuetz P, Aujesky D, Muller C, et al. Biomarker-guided personalised emergency medicine for all - hope for another hype? *Swiss Med Weekly*. 2015;145:w14079.

25. Schuetz P, Christ-Crain M, Huber AR, et al. Long-term stability of procalcitonin in frozen samples and comparison of Kryptor and VIDAS automated immunoassays. *Clin Biochem*. 2010;43:341–344.
26. Schuetz P, Chiappa V, Briel M, et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. *Arch Intern Med*. 2011;171:1322–1331.
27. de Jager CP, van Wijk PT, Mathoera RB, et al. Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. *Crit Care (London, England)*. 2010;14:R192.
28. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Gac Sanit*. 2008;22:144–150.
29. Hattori T, Nishiyama H, Kato H, et al. Clinical value of procalcitonin for patients with suspected bloodstream infection. *Am J Clin Pathol*. 2014;141:43–51.
30. Arai T, Kumasaka K, Nagata K, et al. Prediction of blood culture results by measuring procalcitonin levels and other inflammatory biomarkers. *Am J Emerg Med*. 2014;32:330–333.
31. Magrini L, Gagliano G, Travaglino F, et al. Comparison between white blood cell count, procalcitonin and C reactive protein as diagnostic and prognostic biomarkers of infection or sepsis in patients presenting to emergency department. *Clin Chem Lab Med*. 2014;52:1465–1472.
32. Schuetz P, Litke A, Albrich WC, et al. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. *Curr Opin Infect Dis*. 2013;26:159–167.
33. Howell MD, Talmor D, Schuetz P, et al. Proof of principle: the predisposition, infection, response, organ failure sepsis staging system. *Crit Care Med*. 2011;39:322–327.
34. Singh M, Koyfman A. What is the role of procalcitonin in early diagnosis of infective endocarditis? *Ann Emerg Med*. 2015;66:25–26.
35. Schuetz P, Grolimund E, Kutz A, et al. Procalcitonin-guided antibiotic therapy in patients with congestive heart failure and suspicion of lower respiratory tract infection: results from a randomized trial. *Crit Care*. 2013;17:S12.
36. Schuetz P, Kutz A, Grolimund E, et al. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. *Int J Cardiol*. 2014;175:464–472.